Your browser doesn't support javascript.
loading
Real life thromboprophylaxis in orthopedic surgery in Italy. Results of the GIOTTO study.
Randelli, Filippo; Cimminiello, Claudio; Capozzi, Michele; Bosco, Mario; Cerulli, Giuliano.
Afiliação
  • Randelli F; IRCCS, Policlinico San Donato, San Donato Milanese, Milan, Italy.
  • Cimminiello C; Department of Medicine, Vimercate Hospital Azienda Ospedaliera di Desio e Vimercate, Vimercate, Italy. Electronic address: claudio.cimminiello@aovimercate.org.
  • Capozzi M; Department of Orthopedics, Santa Maria Hospital, Bari, Italy.
  • Bosco M; Anesthesiology and Intensive Care Unit, Catholic University of Sacred Heart, Rome, Italy.
  • Cerulli G; Institute of Orthopedic and Traumatology, "Agostino Gemelli" Hospital, Catholic University, Rome, Italy; Institute of Translational Research for Musculoskeletal System "Nicola Cerulli", Arezzo, Italy.
Thromb Res ; 137: 103-107, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26581636
INTRODUCTION: Data from a prospective, multicentre observational study (Studio GIOTTO) were analyzed to determine, in clinical practice, the pattern of VTE prophylaxis and adherence to international guidelines recommendations in major orthopedic surgery (MOS) - including total hip arthroplasty (THA), total knee arthroplasty (TKA) and hip fracture surgery (HFS) - and knee arthroscopic surgery (KAS). METHODS: In 2010, the first consecutive 30 patients hospitalized in Italian centers for MOS and the first 15 for KAS were enrolled and treated according to the usual practice. RESULTS: 2010 patients were admitted for MOS (577 TKA, 787 THA and 646 HFS) and 993 for KAS; mean ± SD age was 71.7 ± 8 and 43.0 ± 15 years, and female prevalence was 65.6% and 31.1% in MOS and KAS, respectively. Most (66.7%; 95% CI: 65-69%) patients admitted for MOS received a combined VTE prophylaxis, consisting of both pharmacological and physical tools, and 33.2% (95% CI: 31-35%) only pharmacological. For KAS figures were 23.7 (95% CI: 21-26%) and 75.3% (95% CI: 72-77%). Most MOS (91%; 95% CI: 89-92%) and KAS (95% CI: 98-100%) patients receiving pharmacological thromboprophylaxis were treated with low molecular weight heparin (LMWH), for (median) 40 days in TKR, 39 days in THR, 44 in HFS, and 16 in KAS. Patients receiving <35 days of LMWH prophylaxis among those undergoing THR and HFS were 8.9% and 5.9%, respectively. CONCLUSION: Although most patients undergoing orthopedic surgery received VTE prophylaxis, a gap between clinical practice and international guideline recommendations was observed. The reduced adherence to guideline recommendations is relevant for certain choices like type and duration of VTE, and physicians' behavior may reflect the changing approach of guidelines in their different editions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Medicação / Guias de Prática Clínica como Assunto / Heparina de Baixo Peso Molecular / Procedimentos Ortopédicos / Tromboembolia Venosa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pré-Medicação / Guias de Prática Clínica como Assunto / Heparina de Baixo Peso Molecular / Procedimentos Ortopédicos / Tromboembolia Venosa Idioma: En Ano de publicação: 2016 Tipo de documento: Article